1. Home
  2. EKSO vs PPBT Comparison

EKSO vs PPBT Comparison

Compare EKSO & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ekso Bionics Holdings Inc.

EKSO

Ekso Bionics Holdings Inc.

HOLD

Current Price

$4.67

Market Cap

7.7M

Sector

Health Care

ML Signal

HOLD

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

HOLD

Current Price

$0.75

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EKSO
PPBT
Founded
2005
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
7.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EKSO
PPBT
Price
$4.67
$0.75
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$7.75
N/A
AVG Volume (30 Days)
315.9K
784.3K
Earning Date
10-28-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,749,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$54.65
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.73
$0.53
52 Week High
$14.97
$5.20

Technical Indicators

Market Signals
Indicator
EKSO
PPBT
Relative Strength Index (RSI) 51.75 45.28
Support Level $3.50 $0.78
Resistance Level $4.93 $0.87
Average True Range (ATR) 0.40 0.07
MACD 0.06 -0.00
Stochastic Oscillator 81.25 13.50

Price Performance

Historical Comparison
EKSO
PPBT

About EKSO Ekso Bionics Holdings Inc.

Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Share on Social Networks: